Entinostat

Colon Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 40/ 100
Competitive Position: 89/ 100

Competitive context

47 Active assets in the Colon Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
Eloxatin Sun Yat-sen University	Phase 3	BBB
FLUOROURACILUM Merck Sharp & Dohme LLC	Phase 3	BBB
Irinotecan Sun Yat-sen University	Phase 3	BBB
Cetuximab Merck Sharp & Dohme LLC	Phase 3	BB
Nivolumab IFOM ETS - The AIRC Institute of Molecular Oncology	Phase 3	BB

View all 50 →

Same molecule, other indications

Entinostat is also rated in:

Stage IIIA Non-Small Cell Lung CancerDormant

BB

Indicative ·

69 / 100

triple-negative breast carcinomaDormant

B

Indicative ·

63 / 100

myelodysplastic syndromeDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.